About Bolder Science

Our mission is to provide healthcare professionals with unbiased clinical research information, easily.

Currently, you can access the following clinical trials being conducted worldwide:

359,057 studies
in
219 countries
Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 01/22/2021.
This website is for US healthcare professionals

Log In to Bolder Science

or

Don't have an account? Sign Up

Please enter your email address.

You will receive a link to create a new password via email.

Log In

Create an Account

or
(optional) ?

Welcome, !

Please complete the following 4 questions to ensure you receive the information that best suits your needs.

Clinical Trials of Interest

When I’m looking for information on clinical trials, I usually am interested in...

finding clinical trials in which to enroll my patients

Rarely Often

finding newly launched clinical trials (for all phases)

Rarely Often

updates on status changes for clinical trials

Rarely Often

pipeline molecules

Rarely Often

Drug Interventions

Enter up to 3 drug interventions you are currently interested in:

Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 01/22/2021.

Effect of Probiotic on Oral Health of Children

Clinicaltrials.gov identifier NCT03919838

Recruitment Status Recruiting

First Posted April 18, 2019

Last update posted October 31, 2019

Study Description

Brief summary:

The aim of the randomized, double-blind clinical trial with placebo is to answer the clinical question , or in children with diagnosed childhood early caries the use of L.salivarius and cranberry contained in NutroPharma lozenges will reduce new carious lesions and reduce the titre of the carcinogenic bacteria Streptococcus mutans, compared to the control group in which the placebo will be administered? The main end point will be to reduce the titre of cariogenic bacteria.

  • Condition or Disease:Oral Disease
  • Intervention/Treatment: Dietary Supplement: Probiotics
    Dietary Supplement: Placebo - No probiotics
  • Phase: N/A
Detailed Description

Probiotic bacteria are used in the prevention and treatment of gastrointestinal diseases and infections, including the treatment of oral diseases. Probiotic bacteria can be found in saliva, plaque and adhering directly to the mucous membrane. They compete with cariogenic bacteria and pathogens of periodontal disease. Increased interest in probiotics means that attempts are being made to find new solutions regarding the methods of their administration. The use of probiotic bacteria brings beneficial health effects. Lactobacillus salivarius is a strain isolated from human milk. It is inactive (heat treatment) and therefore does not produce metabolites that can promote the formation of carious lesions in the mouth by lowering the mouth potential of hydrogen.

Study Design
  • Study Type: Interventional
  • Estimated Enrollment: 80 participants
  • Allocation: Randomized
  • Intervention Model: Parallel Assignment
  • Intervention Model Description: Parallel Assignment
  • Masking: Triple (Participant, Care Provider, Outcomes Assessor)
  • Primary Purpose: Prevention
  • Official Title: Effect of Probiotic Lactobacillus Salivarius and Cranberry on Oral Health of Children
  • Actual Study Start Date: July 2019
  • Estimated Primary Completion Date: December 2019
  • Estimated Study Completion Date: December 2019
Arms and interventions
Arm Intervention/treatment
Active Comparator: Probiotics
Participants will receive two lozenges containing probiotic bacteria and cranberry.
Dietary Supplement: Probiotics
A half of the participants will be randomly allocated to the probiotics group. They will receive two probiotics lozenge before falling asleep for 8 weeks. Clinical examination will be conducted before study and after 8 weeks.
Placebo Comparator: Placebo - No probiotics
Participants will receive a control two lozenges containing no probiotic bacteria.
Dietary Supplement: Placebo - No probiotics
A half of the participants will be randomly allocated to the placebo group. They will receive two no probiotics lozenge before falling asleep for 8 weeks. Clinical examination will be conducted before study and after 8 weeks.
Outcome Measures
  • Primary Outcome Measures: 1. Changing the titre of the carcinogenic bacteria Streptococcus mutans [ Time Frame: 8 weeks ]
    During control tests saliva will be applied to the medium for identification and detailed quantification of S. mutans bacteria. After the incubation, the number of bacteria will be expressed - taking into account the degree of saliva dilution - as the number of colony-forming unit (CFU) in 1 ml of saliva.
Eligibility Criteria
  • Ages Eligible for Study: 3 to 6 Years (Child)
  • Sexes Eligible for Study: All
  • Accepts Healthy Volunteers: Yes
Criteria

Inclusion Criteria:

- generally healthy children aged 3-6;

- recognized caries of early childhood, dmf> 1,

- lack of active caries and inflammation of the mouth

- colony forming unit CFU > 105 / ml Streptococcus mutans

- a minimum of one-month period from: the last antibiotic therapy, probiotic use,
professional fluoride prophylaxis or supervised tooth brushing with fluoride
preparations, the use of fluoride toothpaste, not using xylitol, written consent of
parents / legal guardians for participation in research.

Exclusion Criteria:

- chronic diseases and chronically taken medicines in the past,

- planned change of residence during the year,

- age below 3 and above 6 years,

- healthy teeth, dmf = 0,

- colony forming unit CFU <105 / ml Streptococcus mutans - Patient during antibiotic therapy, probiotic use, professional fluoride prophylaxis or supervised tooth brushing with fluoride preparations - no toothpaste with fluoride - using xylitol - lack of written consent of parents / legal guardians for participation in research.

Contacts and Locations
Contacts
Locations

Poland, Warsaw, 18 Miodowa Saint
Dorota Olczak-Kowalczyk
Warsaw

Sponsors and Collaborators

Medical University of Warsaw

NutroPharma

More Information
  • Responsible Party: Medical University of Warsaw
  • ClinicalTrials.gov Identifier: NCT03919838 History of Changes
  • Other Study ID Numbers: KB/232/2016
  • First Posted: April 18, 2019 Key Record Dates
  • Last Update Posted: October 31, 2019
  • Last Verified: June 2019
  • Studies a U.S. FDA-regulated Drug Product: No
  • Studies a U.S. FDA-regulated Device Product: No
  • Keywords provided by Medical University of Warsaw: probiotic
    oral health
    children
  • Additional relevant MeSH terms: Mouth Diseases